Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

• Shiratori, Souichi

• Fujimoto, Katsuya

• Nishimura, Machiko

• Hatanaka, Kanako C.

• Kosugi-Kanaya, Mizuha

• Okada, Kohei

• Sugita, Junichi

• Shigematsu, Akio

• Hashimoto, Daigo

• Endo, Tomoyuki

• Kondo, Takeshi

• Abe, Riichiro

• Hashino, Satoshi

• Matsuno, Yoshihiro

• Shimizu, Hiroshi

• Teshima, Takanori

書誌事項

タイトル別名

• RIC-HSCT for MF/SS

抄録

Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS. With a median follow-up period of 954days after HSCT, the estimated 3-year overall survival was 85.7% (95% confidence interval, 33.4-97.9%) with no non-relapse mortality. Five patients relapsed after RIC-HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft-versus-lymphoma effect and "down-staging" effect from advanced stage to early stage by HSCT improve the prognosis of advanced-stage MF/SS. These results suggest that RIC-HSCT is an effective treatment for advanced MF/SS.

収録刊行物

• Hematological oncology

  Hematological oncology 34 (1), 9-16, 2016-03

  Wiley

キーワード

• mycosis fungoides
• Sezary syndrome
• allogeneic hematopoietic stem cell transplantation
• reduced-intensity conditioning
• graft-versus-lymphoma effect

詳細情報

• CRID: 1050001339020449408
• NII論文ID: 120005981361
• HANDLE: 2115/64629
• ISSN: 02780232
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles